22,811 Shares in Masimo Corporation $MASI Acquired by Capricorn Fund Managers Ltd

Capricorn Fund Managers Ltd bought a new position in shares of Masimo Corporation (NASDAQ:MASI) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,811 shares of the medical equipment provider’s stock, valued at approximately $4,057,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Global Retirement Partners LLC bought a new position in shares of Masimo in the 4th quarter worth $27,000. Aster Capital Management DIFC Ltd bought a new stake in Masimo during the fourth quarter valued at about $28,000. Los Angeles Capital Management LLC purchased a new position in Masimo in the fourth quarter valued at about $31,000. Rothschild Investment LLC grew its stake in Masimo by 12,950.0% in the fourth quarter. Rothschild Investment LLC now owns 261 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 259 shares during the last quarter. Finally, Torren Management LLC bought a new position in Masimo in the fourth quarter worth about $35,000. Institutional investors own 85.96% of the company’s stock.

Masimo Price Performance

Masimo stock opened at $179.95 on Wednesday. Masimo Corporation has a 1-year low of $125.94 and a 1-year high of $179.99. The business has a fifty day moving average price of $179.06 and a 200-day moving average price of $163.86. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.68 and a quick ratio of 1.45. The stock has a market capitalization of $9.42 billion, a price-to-earnings ratio of -17.07, a PEG ratio of 1.82 and a beta of 1.11.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Weiss Ratings raised shares of Masimo from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, May 6th. Wells Fargo & Company raised shares of Masimo to a “hold” rating in a research report on Wednesday, March 18th. Finally, Raymond James Financial lowered shares of Masimo from an “outperform” rating to a “market perform” rating in a research note on Friday, March 27th. Nine investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $180.40.

Masimo Company Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.